

# Ashley A Leech

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/859218/publications.pdf>

Version: 2024-02-01

26  
papers

529  
citations

933447

10  
h-index

839539

18  
g-index

26  
all docs

26  
docs citations

26  
times ranked

884  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Cost-Effectiveness of Operating on Traumatic Spinal Injuries in Low-Middle Income Countries: A Preliminary Report From a Major East African Referral Center. <i>Global Spine Journal</i> , 2022, 12, 15-23. | 2.3 | 12        |
| 2  | Medicaid prevalence and opioid use disorder treatment access disparities. <i>Health Services Research</i> , 2022, 57, 422-429.  | 2.0 | 6         |
| 3  | Modelling the potential cost-effectiveness of food-based programs to reduce malnutrition. <i>Global Food Security</i> , 2021, 29, 100550.   | 8.1 | 10        |
| 4  | Author's Reply. <i>Value in Health</i> , 2021, 24, 1086-1087.   | 0.3 | 0         |
| 5  | A Comparison of Methods to Identify Antenatal Substance Use Within Electronic Health Records. <i>American Journal of Obstetrics &amp; Gynecology</i> MFM, 2021, , 100535.                                   | 2.6 | 0         |
| 6  | Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia. <i>Value in Health</i> , 2020, 23, 1292-1299.  | 0.3 | 9         |
| 7  | HIV Pre-Exposure Prophylaxis for Conception Among HIV Serodiscordant Couples in the United States: A Cohort Study. <i>AIDS Patient Care and STDs</i> , 2020, 34, 295-302.                                   | 2.5 | 5         |
| 8  | Healthcare practitioner experiences and willingness to prescribe pre-exposure prophylaxis in the US. <i>PLoS ONE</i> , 2020, 15, e0238375.  | 2.5 | 9         |
| 9  | Association of Pregnancy and Insurance Status With Treatment Access for Opioid Use Disorder. <i>JAMA Network Open</i> , 2020, 3, e2013456.  | 5.9 | 84        |
| 10 | Neonatal Abstinence Syndrome In The United States, 2004-2016. <i>Health Affairs</i> , 2020, 39, 764-767.  | 5.2 | 44        |
| 11 | Balancing Value with Affordability: Cell Immunotherapy for Cancer Treatment in the U.S.. <i>Oncologist</i> , 2020, 25, e1117-e1119.   | 3.7 | 5         |
| 12 | Are low and middle-income countries prioritising high-value healthcare interventions?. <i>BMJ Global Health</i> , 2020, 5, e001850.   | 4.7 | 13        |
| 13 | Healthcare practitioner experiences and willingness to prescribe pre-exposure prophylaxis in the US. , 2020, 15, e0238375.  |     | 0         |
| 14 | Healthcare practitioner experiences and willingness to prescribe pre-exposure prophylaxis in the US. , 2020, 15, e0238375.  |     | 0         |
| 15 | Healthcare practitioner experiences and willingness to prescribe pre-exposure prophylaxis in the US. , 2020, 15, e0238375.  |     | 0         |
| 16 | Healthcare practitioner experiences and willingness to prescribe pre-exposure prophylaxis in the US. , 2020, 15, e0238375.  |     | 0         |
| 17 | Healthcare practitioner experiences and willingness to prescribe pre-exposure prophylaxis in the US. , 2020, 15, e0238375.  |     | 0         |
| 18 | Healthcare practitioner experiences and willingness to prescribe pre-exposure prophylaxis in the US. , 2020, 15, e0238375.  |     | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions. <i>Pharmacoeconomics</i> , 2019, 37, 597-608.  | 3.3 | 46        |
| 20 | Cost-Effective But Unaffordable: The CAR-T Conundrum. <i>Journal of the National Cancer Institute</i> , 2019, 111, 644-645.  | 6.3 | 12        |
| 21 | Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. <i>Value in Health</i> , 2018, 21, 759-761.   | 0.3 | 108       |
| 22 | Assessing access to assisted reproductive services for serodiscordant couples with human immunodeficiency virus infection. <i>Fertility and Sterility</i> , 2018, 109, 473-477.  | 1.0 | 10        |
| 23 | Cost-Effectiveness Thresholds: the Past, the Present and the Future. <i>Pharmacoeconomics</i> , 2018, 36, 509-522.   | 3.3 | 124       |
| 24 | Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States. <i>Aids</i> , 2018, 32, 2787-2798.   | 2.2 | 7         |
| 25 | Implementing a Pre-Exposure Prophylaxis Intervention for Safer Conception among HIV Serodiscordant Couples: Recommendations for Health Care Providers. <i>Journal of Health Disparities Research and Practice</i> , 2018, 11, 19-33. | 1.1 | 3         |
| 26 | Experiences Using Pre-Exposure Prophylaxis for Safer Conception Among HIV Serodiscordant Heterosexual Couples in the United States. <i>AIDS Patient Care and STDs</i> , 2017, 31, 348-355.   | 2.5 | 22        |